Login to Your Account



Chi-Med botanical sees defeat in phase III for UC; pipeline hopes remain

By Shannon Ellis
Staff Writer

Tuesday, August 26, 2014
SHANGHAI – Hutchison China Meditech Ltd., also known as Chi-Med, said this month that phase III trials would be terminated for its lead candidate, HMPL-004, a botanical treatment for ulcerative colitis (UC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription